Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant five-antigen Staphylococcus aureus vaccine
- Development stage
- Phase 1
- Lead developer
- Olymvax
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The recombinant five-antigen Staphylococcus aureus vaccine, also known as the rStaph vaccine, is a protein subunit vaccine developed by Olymvax Biopharmaceuticals. It is produced using an E. coli expression system and contains five key recombinant antigens: alpha-hemolysin (Hla), Panton-Valentine leukocidin (PVL) subunits LukS and LukF, clumping factor A (ClfA), and staphylococcal enterotoxin B (SEB). The vaccine is designed to provide broad protection against Staphylococcus aureus infections by inducing neutralizing antibodies that inhibit bacterial adhesion and neutralize potent toxins. It is currently in Phase III clinical trials in China, specifically targeting the prevention of surgical site infections in patients undergoing orthopaedic surgery.
- Other names
- recombinant Staphylococcus aureus vaccine (E. coli)5-antigen S. aureus vaccine
02
Targets
Hla (Staphylococcus aureus alpha toxin)SEB (Staphylococcal enterotoxin B)IsdB (Iron surface determinant B)MntC (Staphylococcus aureus manganese transport protein C)
Beyond the preview
Go deeper on recombinant five-antigen Staphylococcus aureus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant five-antigen Staphylococcus aureus vaccine.